Today’s Rating On Watch: Researchers at RBC Capital Markets Maintained their Sector Perform rating for Valeant Pharmaceuticals (TSE:VRX). The Target Price is $39.00

November 28, 2016 - By Michael Collier

Valeant Pharmaceuticals (TSE:VRX) Rating

RBC Capital Markets have a $39.00 PT on the stock. The PT would indicate a potential upside of 65.96% from Valeant Pharmaceuticals (TSE:VRX)‘s last price. This rating was revealed in a research report on Monday, 28 November.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 3 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. $74 is the highest target while $17 is the lowest. The $31.33 average target is 32.92% above today’s ($23.57) stock price. Valeant Pharmaceuticals International has been the topic of 17 analyst reports since October 20, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the shares of VRX in a report on Tuesday, May 24 with “Sector Perform” rating. The stock has “Outperform” rating given by RBC Capital Markets on Tuesday, October 20. The company was maintained on Wednesday, July 20 by TD Securities. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) has “Sector Perform” rating given on Tuesday, September 20 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Sector Perform” on Monday, October 31. The company was maintained on Tuesday, January 26 by RBC Capital Markets. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (TSE:VRX) rating on Friday, June 3. RBC Capital Markets has “Sector Perform” rating and $74 price target. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, October 11. As per Friday, November 18, the company rating was maintained by RBC Capital Markets. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, October 25.

About 685,159 shares traded hands. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 49.62% since April 22, 2016 and is downtrending. It has underperformed by 55.63% the S&P500.

Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on March, 21. They expect $1.34 earnings per share, down 46.61% or $1.17 from last year’s $2.51 per share. VRX’s profit will be $458.10M for 3.28 P/E if the $1.34 EPS becomes a reality. After $1.55 actual earnings per share reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts -13.55% negative EPS growth.

Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.02, from 0.86 in 2016Q1. The ratio improved, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.

Edge Wealth Management Limited Liability Corporation last reported 3,100 shares in the company. Moreover, Baldwin Brothers Ma has 0% invested in Valeant Pharmaceuticals Intl Inc (TSE:VRX) for 250 shares. Moreover, Qs has 0.01% invested in Valeant Pharmaceuticals Intl Inc (TSE:VRX) for 85,789 shares. Delta Lloyd Nv has 0.02% invested in the company for 22,319 shares. Credit Suisse Ag last reported 0.02% of its portfolio in the stock. Goldman Sachs Inc holds 0.04% of its portfolio in Valeant Pharmaceuticals Intl Inc (TSE:VRX) for 6.34M shares. Jackson Park Lc holds 0.58% or 21,000 shares in its portfolio. Parametric Port Associate Ltd Liability Company last reported 38,620 shares in the company. First Eagle Inv Management Ltd Limited Liability Company has invested 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (TSE:VRX). Fil Ltd last reported 16,671 shares in the company. Lonestar Cap Limited Company last reported 0.27% of its portfolio in the stock. Capital Guardian last reported 0% of its portfolio in the stock. Susquehanna Intl Group Limited Liability Partnership has 0.06% invested in the company for 5.24 million shares. Deutsche Bank & Trust Ag last reported 194,448 shares in the company. Moreover, Endurant Capital Management L P has 0.27% invested in Valeant Pharmaceuticals Intl Inc (TSE:VRX) for 40,100 shares.

Insider Transactions: Since June 9, 2016, the stock had 2 buys, and 0 sales for $5.04 million net activity. On Thursday, June 9 the insider PAPA JOSEPH C bought $4.94 million. 4,000 shares were bought by KARABELAS ARGERIS N, worth $98,600 on Thursday, August 11.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $7.86 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Profitconfidential.com which released: “Valeant Pharmaceuticals Intl Inc: More Bad News for VRX Stock” on November 24, 2016, also Fool.com with their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016, Fool.com published: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” on November 01, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Investorplace.com and their article: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” published on November 15, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” with publication date: November 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>